For 2 years, the authors followed 22 newly diagnosed children with PWS (mean age of 12.9 months at study onset) divided into two groups: (1) 10 participants administered GH for 24 months, and (2) 10 participants administered GH after 6 months of a control period (40). Here, GH1 is linked to Prader-Willi syndrome.